Dr. Roy Herbst, LCRF Scientific Advisory Board member, spoke with OncLive recently about the progress made in 2021 in lung cancer treatment. He also noted the need for more research to address acquired resistance.
The latest class of LCRF grant recipients includes several investigators whose projects are aimed at understanding and solving acquired resistance to targeted therapy. LCRF remains committed to funding science that addresses unmet need in lung cancer research, providing hope for people with a lung cancer diagnosis. #Research is our #TrueNorth.